drugset
drugset / Trial / NCT03878823

Safety and Pharmacokinetics of ODM-209

NCT03878823 ↗

Phase 1/2 Completed 38 enrolled Orion Corporation, Orion Pharma
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this first-in-human study is to evaluate safety and tolerability of ODM-209 and find the dose of ODM-209.

Timeline

Start
2019-04-17
Primary completion
2024-01-09
Completion
2024-01-09

Drugs

EvaluationDrugModalityDoseRoute
Subject ODM-209 Unknown — Oral

Indications

castration-resistant prostate carcinoma female breast carcinoma metastatic neoplasm metastatic prostate carcinoma